Clinical Study
Serum Fatty Acids and Risk of Cutaneous Melanoma: A Population-Based Case-Control Study
Table 3
Odds ratio (OR) with 95% confidence intervals (CI) of melanoma by tertile of serum fatty acid percentage composition.
| | Ia | II | III | trend | | OR | OR | (95% CI) | OR | (95% CI) |
| SFAsb | | | | | | | Palmitic | 1.00 | 1.00 | (0.37–2.71) | 0.75 | (0.23–2.41) | 0.568 | Margaric (daturic) | 1.00 | 0.85 | (0.30–2.47) | 1.29 | (0.40–4.21) | 0.783 | Stearic | 1.00 | 1.48 | (0.50–4.42) | 1.94 | (0.61–6.20) | 0.115 | Arachidic | 1.00 | 1.76 | (0.44–7.02) | 2.13 | (0.61–7.46) | 0.400 | Lignoceric | 1.00 | 0.69 | (0.24–1.99) | 0.57 | (0.18–1.77) | 0.725 | MUFAsb | | | | | | | Oleic | 1.00 | 1.02 | (0.42–2.46) | 1.23 | (0.44–3.45) | 0.909 | Nervonic | 1.00 | 1.79 | (0.51–6.24) | 1.59 | (0.32–7.94) | 0.876 | PUFAsb | | | | | | | Linoleic | 1.00 | 0.73 | (0.27–1.98) | 0.77 | (0.28–2.15) | 0.406 | Arachidonic | 1.00 | 0.57 | (0.21–1.55) | 1.33 | (0.53–3.33) | 0.402 | EPA | 1.00 | 2.17 | (0.68–6.90) | 1.16 | (0.30–4.43) | 0.600 | DPA | 1.00 | 1.2 | (0.44–3.24) | 1.00 | (0.34–2.91) | 1.000 | DHA | 1.00 | 0.65 | (0.22–1.90) | 0.67 | (0.24–1.86) | 0.891 | Groupings | | | | | | | SFAs | 1.00 | 0.41 | (0.11–1.48) | 1.65 | (0.49–5.51) | 0.589 | MUFAs + PUFAs | 1.00 | 0.81 | (0.31–2.16) | 0.76 | (0.23–2.55) | 0.884 | MUFAs | 1.00 | 0.95 | (0.35–2.59) | 1.08 | (0.36–3.24) | 0.932 | PUFAs | 1.00 | 0.57 | (0.20–1.64) | 0.78 | (0.27–2.21) | 0.859 | SFAs/MUFAs + PUFAs | 1.00 | 1.03 | (0.33–3.25) | 1.25 | (0.41–3.81) | 0.907 | SFAs/PUFAs | 1.00 | 0.71 | (0.26–1.95) | 1.33 | (0.50–3.46) | 0.478 | n-3 PUFAs | 1.00 | 0.82 | (0.24–2.71) | 1.11 | (0.37–3.36) | 0.718 | n-6 PUFAs | 1.00 | 0.61 | (0.21–1.74) | 0.90 | (0.33–2.47) | 0.807 | n-3 PUFAs/n-6 PUFAs | 1.00 | 1.99 | (0.73–5.26) | 1.31 | (0.42–4.02) | 0.679 |
|
|
aReferent group.
bSFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids.
|